Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 31, 2024 05:00 ET | Source: NRG Therapeutics Limited

NRG Therapeutics Selects First Development Candidate, NRG5051, and Secures Grant from The Michael J. Fox Foundation for Development of mPTP Inhibitors to Treat Neurodegenerative Diseases

First development candidate selected, NRG5051, with potential to treat Parkinson’s and Amyotrophic Lateral Sclerosis (ALS) (also known as Motor Neuron Disease, MND) and other neurodegenerative...
September 05, 2024 04:00 ET | Source: NRG Therapeutics Limited

NRG Therapeutics Awarded Grant Funding from Target ALS to Support the Development of mPTP Inhibitors as Novel Treatments for ALS/MND

STEVENAGE, United Kingdom, Sept. 05, 2024 (GLOBE NEWSWIRE) -- NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has been...
April 26, 2023 04:00 ET | Source: NRG Therapeutics Limited

NRG Therapeutics Appoints Dr Jonathan Savidge as Independent Chair

STEVENAGE, United Kingdom, April 26, 2023 (GLOBE NEWSWIRE) -- NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has...
April 19, 2023 04:00 ET | Source: NRG Therapeutics Limited

NRG Therapeutics Appoints Vad Lazari Ph.D. as Vice President of Biology to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders

Vad Lazari Ph.D., appointed to the newly created position of VP of Biology, based in Stevenage, UKJoins from Charles River and brings two decades of drug discovery experience including at Pfizer and...
March 30, 2023 04:00 ET | Source: NRG Therapeutics Limited

NRG Therapeutics Announces International Scientific Advisory Board

STEVENAGE, United Kingdom, March 30, 2023 (GLOBE NEWSWIRE) -- NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce the formation of...
February 22, 2023 04:00 ET | Source: NRG Therapeutics Limited

NRG Therapeutics Awarded Second $500K Grant from The Michael J. Fox Foundation to Further Progress Parkinson’s Programme

STEVENAGE, United Kingdom, Feb. 22, 2023 (GLOBE NEWSWIRE) -- NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has been...
February 09, 2023 04:01 ET | Source: NRG Therapeutics Limited

NRG Therapeutics Appoints Gilles Ouvry Ph.D. as Vice President of Chemistry to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders

Gilles Ouvry Ph.D, appointed to newly created position of VP of Chemistry, based in Stevenage, UKJoins from Evotec, UK and brings 20 years of international medicinal chemistry experience including at...